Abstract-Nuclear factor kappa B (NF-B) participates in hypertension-induced vascular and target-organ damage. We tested whether or not endothelial cell-specific NF-B suppression would be ameliorative. We generated Cre/lox transgenic mice with endothelial cell-restricted NF-B super-repressor IB␣⌬N (Tie-1-⌬N mice) overexpression. We confirmed cell-specific IB␣⌬N expression and reduced NF-B activity after TNF-␣ stimulation in primary endothelial cell culture. To induce hypertension with target-organ damage, we fed mice a high-salt diet and N(omega)-nitro-Larginine-methyl-ester (L-NAME) and infused angiotensin (Ang) II. This treatment caused a 40-mm Hg blood pressure increase in both Tie-1-⌬N and control mice. In contrast to control mice, Tie-1-⌬N mice developed a milder renal injury, reduced inflammation, and less albuminuria. RT-PCR showed significantly reduced expression of the NF-B targets VCAM-1 and ICAM-1, compared with control mice. Thus, the data demonstrate a causal link between endothelial NF-B activation and hypertension-induced renal damage. We conclude that in vivo NF-B suppression in endothelial cells stops a signaling cascade leading to reduced hypertension-induced renal damage despite high blood pressure. Key Words: hypertension Ⅲ endothelium Ⅲ NF-B Ⅲ target-organ damage H ypertension is a risk factor for target-organ damage such as cardiac and renal disease. 1 Endothelial cell injury initiates adhesion molecule and chemokine expression promoting inflammation that contributes to the pathogenesis of hypertension-induced target organ damage. [2] [3] [4] [5] Patients with severe hypertension and target-organ damage often show elevated angiotensin (Ang) II levels and reduced nitric oxide (NO) production. Ang II signaling blockade reduces blood pressure and blunts the development and progression of vascular disease in small and large vessels in experimental animal models and in humans. Ang II also elicits an inflammatory response in both endothelial cells 6 and vascular smooth muscle cells. 7, 8 Numerous in vitro and in vivo studies demonstrated that Ang II activates the nuclear factor kappa B (NF-B), a major transcription factor in mediating inflammation and innate immunity. 4,6 -8 In resting cells, NF-B resides inactive in the cytoplasm by forming complexes with the inhibitor of B (I〉) proteins. Exposure to extracellular stimuli like TNF-␣, IL-1, reactive oxygen species, Ang II, and numerous other activators leads to rapid phosphorylation, site-specific ubiquitination, and subsequent degradation of the IB proteins by the 26S proteasome. 9 The resulting free NF-B molecules translocate to the nucleus and regulate target gene expression. The targets include genes involved in the control of cell proliferation, apoptosis, innate, and adaptive immune response. 10,11 NF-B and inflammation play an important role in the development of the target organ damage. 4, [12] [13] [14] [15] [16] [17] However, inhibition of NF-B signaling could also be detrimental. 18, 19 Furthermore, the ideal site for NF-B inhibition in the vessel wall is unknown. To address the role of NF-B in the endothelium in hypertension-induced renal damage, we used the Cre/lox technique to generate a novel mouse model with endothelial cell-restricted expression of the human NF-B super-repressor IB␣⌬N. 14,20
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Materials and Methods

Mice
For endothelial cell-restricted super-repressor IB␣⌬N overexpression, mice carrying loxP-flanked alleles encoding for the human IB␣⌬N (loxP-⌬N) were crossed with Cre knock-in mice expressing the Cre recombinase under the control of endothelial-specific Tie-1 promoter. Tie-1-Cre mice were a gift from Dr Erika Gustafsson. 21 The loxP-⌬N mice were described previously. 14, 20 The Tie-1-Cre knock-in mediates excision of loxP-flanked sequences in renal, cardiac, pulmonary, and aortic endothelial cells. 21 The double knock-in mice were designated Tie-1-⌬N. All mice were bred on a C57Bl/6 background for more than 7 generations. The Berlin Animal Review Board approved all protocols (Reg. 0135/01 and G 0261/02).
Ang II/L-NAME Mouse Model
Eight-week-old control mice (single transgenic Tie-1-Cre and loxP-⌬N, wild-type C57BL/6 mice) and Tie-1-⌬N double transgenic mice (nՆ21 for each group) received the NO synthase inhibitor N(omega)-nitro-L-arginine-methyl-ester (L-NAME). L-NAME was given at 0.1 mg⅐mL Ϫ1 in the drinking water. Ang II (1.0 mg⅐kg Ϫ1 ⅐day Ϫ1 ) was infused via ALZET mini pumps. The animals were fed a high-sodium diet (1% sodium in the chow) for 14 days. 22 Because C57BL/6, Tie-1-Cre, and loxP-⌬N mice showed no differences in renal histology, albuminuria, cell infiltration, and gene expression, these groups were combined and termed controls. We measured 24-hour mouse urinary albumin by ELISA (CellTrend, Germany). Animals were killed on day 14 under ether anesthesia. Hearts and kidneys were washed, weighed, harvested, and stored until analysis.
Telemetric Mean Arterial Pressure Measurements
Telemetry system and Dataquest ART 2.0 software from Data Sciences International were used to measure intracarotid blood pressure in 4 to 5 mice per group. Briefly, a telemetry probe catheter (TA11-PA40; Data Sciences International) was inserted into the surgically exposed carotid artery. 23 After surgery, all mice were allowed at least 7 days to recover. Before Ang II/L-NAME treatment, baseline values were continuously recorded for 3 days and averaged. Days 10 to 12 after Ang II/L-NAME treatment, blood pressure and heart rate were recorded and statistically analyzed. Systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate were sampled at 100 Hz. Mean arterial pressure (MAP) was calculated as follows: MAPϭDBPϩ(SBP-DBP)/3.
Immunohistochemistry and In Situ Hybridization
Ice-cold acetone-fixed cryosections (6 m) were stained by indirect immunofluorescence techniques as described earlier. 17 The sections were incubated with the following antibodies: anti-F4/80, anti-CD4 (both serotec, UK), anti-CD3, anti-CD8 (both BD Bioscience, Germany), anti-collagen III (Fitzgerald, Mass), anti-VCAM-1 (SantaCruz, Germany), anti-ICAM-1 (Dianova, Germany), anti-p65 (Abcam, UK), and anti-TNF-␣ (SantaCruz, Germany). For histology and in situ hybridization, paraffin sections were used. Masson trichrome stain was performed by clinical routine protocol. Semiquantification of tubular damage was performed as described in online methods. P65 semiquantification was evaluated with a scoring system 1-5 based on the number of p65ϩ nuclei. Paraffin sections were also stained with sirius red to evaluate the degree of fibrosis. In situ hybridization was performed as described earlier. 24 The murine IB␣ (nt 1 to 1091, U36277/NM010907) cDNA was used. Sections were counterstained with 0.01% PyroninG and mounted with Entellan (Merck). All pictures were taken with a Zeiss Axioplan 2 Imaging microscope/ Axiophot camera.
Endothelial Cell Culture
Murine lung and aortic endothelial cells were isolated with Dynabeads coated with anti-platelet-endothelial cell adhesion molecule-1 or anti-ICAM-2 monoclonal antibody as described previously. 25, 26 Endothelial cells were cultured with DMEM supplemented with 20% FBS, heparin, endothelial cell growth factor, nonessential amino acids, and antibiotics.
Immunoblotting and Electrophoretic Mobility Shift Assay
Endothelial cells were stimulated with TNF-␣ (20 ng/mL; Biomol, Germany) as indicated. Whole cell extracts were prepared as described earlier. 27 electrophoretic mobility shift assay (EMSA) was performed with 5 g whole cell protein as described previously. 27 For immunoblotting, 20 g whole cell lysate protein was used and revealed with an IB␣ antibody (Santa Cruz, Germany).
Quantitative TaqMan RT-PCR
Total kidney RNA was isolated using the TRIZOL protocol; RNA from cells with the RNeasy kit (Qiagen, Germany). TaqMan RT-PCR by SYBR Green analysis was performed as described earlier. 28 ICAM-1 and VCAM-1 mRNA quantities were analyzed in duplicate. For quantification, the target sequences were normalized in relation to the mouse GAPDH product (Clonetech, Germany). Biotez (Berlin, Germany) synthesized the primers. The sequences are listed in the online method section.
Statistical Analysis
Differences between experimental groups were analyzed by use of adjusted student t test or ANOVA for repeated measures, as appropriate. Data are reported as meanϮSEM. Values of PϽ0.05 were considered significant.
Results
Generation of Mice with Endothelial-Specific NF-B Inhibition
The breeding scheme of floxed IB␣⌬N (loxP-⌬N) mice and heterozygous Tie-1-Cre knock-in mice to generate mice with endothelial cell-restricted IB␣⌬N expression, namely Tie-1-⌬N mice, is given ( Figure 1 ). IB␣⌬N lacks the destruction box containing the phosphorylation and ubiquitination sites and acts as a super-repressor of NF-B activity (supplemental Figure I , available online at http://circres.ahajournals.org). To confirm the correct functioning of the Tie-1-Cre line, Tie-1-Cre mice were mated with ROSA26R flox/flox reporter mice and endothelial cell-specific LacZ staining pattern in the aorta was observed (data not shown). These results agree with the previous description of the Tie-1-directed Cre expression. 21, 29 Recombination in Tie-1-⌬N mice was verified by immunoblot analysis of whole cell extracts from isolated primary endothelial cells (Figure 2A ). IB␣⌬N lacks the N-terminal 70 amino acids and thus runs at a smaller molecular weight range than endogenous IB␣ ( Figure 2A ). The efficiency of NF-B inhibition in Tie-1-⌬N was confirmed by EMSA ( Figure 2B and 2C) . After TNF-␣ stimulation, cultured endothelial cells from Tie-1-⌬N showed a reduced NF-B DNAbinding activity, compared with wild-type control cells ( Figure  2C ). Residual induced NF-B activity was most likely derived from nonrecombinant endothelial cells, because the Cre recombinase does not function 100%. Excision of loxP sites by Tie-1 promoter-induced Cre is estimated to take place in 70 and 95% of endothelial cells depending on the organ. 21 Cultured wild-type endothelial cells may grow at a faster rate and eventually outnumber Tie-1-⌬N endothelial cells. Interestingly, in situ hybridization ( Figure 2D ) using a murine anti-sense RNA probe of the bona fide NF-B target gene IB␣ clearly demonstrated that hypertensive control mice with severe renal damage showed strong IB␣ signals in various substructures of the kidney, namely blood vessels, tubules, and glomeruli. The increased IB␣ expression at these sites can be used as a direct read-out for NF-B activity. As expected, in all these structures we observed significantly less upregulation of IB␣ expression in Tie-1-⌬N mice and in sham-controls ( Figure 2D ). This result already suggests that NF-B activity in endothelial cells has a direct effect on NF-B activation in the surrounding structures such as tubules and glomeruli. We analyzed nuclear p65 immunoreactivity as a marker for NF-B activation. Vascular endothelial cells from Ang II/L-NAME-treated control mice often showed p65ϩ nuclei, whereas only a few endothelial cells were positive in from Ang II/L-NAME-treated Tie-1-⌬N mice (supplemental Figure IIA) . Tubular p65 nuclei were significantly less frequent in mice with suppressed NF-B signaling compared with Ang II/L-NAME-treated control mice, but still (supplemental Figure  IIB and IIC) . Reduced endothelial NF-B activity has no effect on blood pressure but reduces albuminuria. A, Telemetric blood pressure recordings of control and Tie-1-⌬N mice. Tie-1-⌬N and control mice are normotensive before Ang II/L-NAME treatment (baseline) but severely hypertensive 14 days after chronic Ang II/L-NAME administration. B, Baseline urinary albumin levels before (baseline) and after 14 days of Ang II/L-NAME treatment. Albuminuria is significantly higher in controls compared with Tie-1-⌬N mice. Results are meanϮSEM. *PϽ0.05 vs baseline; #PϽ0.05 vs Ang II/L-NAME-treated controls. 
NF-B Activation Promotes Hypertension-Induced Renal Damage
Blood pressure recordings revealed that control mice and Tie-1-⌬N mice were normotensive before Ang II/L-NAME treatment (106Ϯ1 mm Hg versus 103Ϯ1 mm Hg, respectively; Figure 3A) . Chronic Ang II/L-NAME administration raised the mean arterial blood pressure (MAP) by 40 mm Hg. There was no difference in MAP between both groups (143Ϯ5 mm Hg for control and 143Ϯ4 mm Hg for Tie-1-⌬N; Figure 3A ). Baseline urinary albumin excretion was also similar between both groups ( Figure 3B ). However, after Ang II/L-NAME treatment, albuminuria was significantly higher in control mice compared with Tie-1-⌬N mice (6876Ϯ1058 versus 3022Ϯ737 g/d, respectively, PϽ0.05; Figure 3B ).
Masson trichrome stain of kidney tissue showed that Ang II/L-NAME-treated control mice had severe tubular and vascular damage with increased matrix production, compared with control mice ( Figure 4A ). Semiquantification of tubular damage supported this result ( Figure 4B ). Ang II/L-NAMEtreated Tie-1-⌬N mice also showed histological changes. Nevertheless, matrix formation and tubular damage were significantly less pronounced in mice with suppressed NF-B signaling compared with Ang II/L-NAME-treated control mice ( Figure 4A and 4B) . Sirius red stains confirmed a significant reduction of perivascular and interstitial fibrosis in Ang II/L-NAME-treated Tie-1-⌬N mice ( Figure 4C ). Vascular damage was less pronounced in Ang II/L-NAMEtreated Tie-1-⌬N compared with control mice (supplemental Figure IIIA) . Suppressed NF-B activity only protected glomeruli to a minor degree. Glomerular collagen III deposition was partially reduced in Ang II/L-NAME-treated Tie-1-⌬N mice (supplemental Figure IIIB) .
NF-B Drives Renal TNF-␣, VCAM-1, and ICAM-1 Expression in Hypertensive Mice
TNF-␣ expression was increased in damaged glomeruli, tubules, and the vessel wall from Ang II/L-NAME-treated controls, significantly reduced in Ang II/L-NAME-treated Tie-1-⌬N mice, and hardly or not expressed in sham controls ( Figure 5 ). RT-PCR analysis revealed that after Ang II/L-NAME treatment renal VCAM-1 ( Figure 6A ) and ICAM-1 ( Figure 6B ) expression was significantly increased in control mice, compared with Tie-1-⌬N mice. Nevertheless, both groups showed significantly increased adhesion molecule expression, compared with untreated normotensive shamcontrol mice ( Figure 6A and 6B) . Immunohistological analysis of renal VCAM-1 ( Figure 6C ) and ICAM-1 ( Figure 6D ) confirmed our RT-PCR results. Interestingly, we observed different expression patterns of VCAM-1 and ICAM-1 immunoreactivity in large or medium arteries, small arterioles, and capillaries. Large and medium arteries, as well as capillaries of treated Tie-1-⌬N mice showed a significantly reduced adhesion molecule expression compared with controls. However, arterioles showed the same staining intensity as treated controls (data not shown). This result suggests insufficient Cre recombination in arterioles. ICAM-1 was also expressed constitutively in the interstitium. However, Ang II/L-NAME-treated Tie-1-⌬N mice showed a significantly reduced renal ICAM-1 immunoreactivity in the interstitium, glomerular bed ( Figure 6D upper panel) , and the vessel wall ( Figure 6D lower panel) compared with Ang II/L-NAME-treated controls.
Renal Inflammatory Cell Infiltration Is Controlled by NF-B
Because of the increased VCAM-1 and ICAM-1 expression in Ang II/L-NAME-treated animals, we analyzed immune cell infiltration in our treated mouse models. Using an anti-CD3 antibody, elevated T-cell infiltration is seen in kidneys of treated control animals and to a lesser degree in Tie-1-⌬N animals ( Figure 7A) . The 2 T cell subpopulations that included CD4 ϩ (helper) and CD8 ϩ (cytotoxic) T-cells, as well as macrophages (F4/80ϩ cells), were primarily located around blood vessels and to a lesser extent within the interstitium. We quantified infiltrating monocytes/macrophages, T cells (CD3 ϩ , CD4 ϩ ), and CD8 ϩ T-cell subpopulations in stained renal sections ( Figure 7B through 7E) . We observed partially diminished renal immune cell infiltration in Ang II/L-NAME-treated-Tie-1-⌬N compared with Ang II/L-NAME-treated control mice ( Figure 7B through 7E) . Nevertheless, cell infiltration was still significantly increased in treated Tie-1-⌬N mice, compared with untreated shamcontrols ( Figure 7B through 7E) .
Discussion
The surprising finding is that endothelial-specific NF-B suppression suffices to ameliorate Ang II/L-NAME hypertension-induced renal damage. The results demonstrate that inhibition of NF-B signaling in a single cell type is able to reduce renal tubular, vascular, and to a minor extent also glomerular damage. Endothelial NF-B inhibition did not affect the development of hypertension, indicating that the renal protection was blood pressureindependent. Our study provides the first in vivo evidence that specific endothelial NF-B inhibition results in a Hypertension is a major risk factor for cardiovascular events. Nevertheless, high blood pressure is not a unique factor in the pathogenesis of target organ damage. We reported earlier that dexamethasone inhibited NF-B activity and prevented renal damage in an Ang II-dependent rat model despite blood pressures exceeding 200 mm Hg. 30 In the present study, Ang II/L-NAME-treated controls and Tie-1-⌬N mice were severely hypertensive and both developed renal damage. Nevertheless, endothelial-specific NF-B suppression protected Tie-1-⌬N mice to a significant extent.
NF-B plays an important role in the pathogenesis of cardiovascular disease. Cardiac NF-B inhibition by a decoy technique reduced the extent of myocardial infarction after reperfusion. 31 In renal allografts, pretreatment of donor kidneys with NF-B decoys led to reduced NF-B activity and expression of VCAM-1 leading to reduced cell infiltration. 32 Boyle et al showed that treatment with pyrrolidine dithiocarbamate (PDTC), a compound which acts as an antioxidant and prevents ubiquitination and degradation of the NF-B inhibitor IB␣, blocked endothelial cell E-selectin expression in vitro and reduced cell infiltration in LPS-infused rabbits. 33 We reported earlier that NF-B inhibition by PDTC ameliorated Ang II-induced cardiac hypertrophy and renal and vascular damage. 4 In fact, PDTC probably not only blocks NF-B activation, because it also inhibits the ubiquitin ligase ␤-TrCP, which is involved in other signaling pathways. 34 Therefore, antioxidative, NF-B, or other signaling pathways might have accounted for the effect in vivo. New strategies with cell-type specific NF-B inhibition as described in this and other recent articles can circumvent this problem. Freund et al 14 were the first to show that in mice with cardiomyocyte-specific NF-B suppression, cardiac hypertrophy was significantly reduced after Ang II treatment. Herrmann et al 15 used a mouse stroke model and showed that suppressed IB kinase (IKK)-2 activity in neurons markedly reduced cerebral infarct size. The animal models described above consider NF-B as a detrimental factor in the pathogenesis of cardiovascular disease.
NF-B also regulates cell survival and plays a fundamental role in normal cell physiology. Thus, NF-B inhibition may also cause harmful effects. For instance, NF-B inhibition in macrophages increased atherosclerosis in LDL receptordeficient mice. 18 Furthermore, deletion of the IKK-NF-B pathway components results in massive hepatic apoptosis, defects in hematopoiesis, and death in utero. [35] [36] [37] A transgenic mouse model similar to the Tie-1-⌬N mice was recently established by Kisseleva et al and differed from ours in the overexpression of a mutated IB␣ under the control of the Tie-2 promoter. 19 In these mice, endothelial cell NF-B inhibition increased the sensitivity to LPS-induced toxemia and altered vascular integrity. Whether or not the 2 models have an identical transmission of the modified IB␣ in the same cell type is difficult to determine without a direct comparison; such a comparison would be interesting and perhaps revealing. One challenging goal for the future will be the elucidation of protective versus harmful effects of NF-B in cardiovascular disease. These effects seem to be cell-and time-dependent. More detailed studies are needed to investigate this important controversy.
In contrast to atherosclerosis, hypertension-induced vascular injury is not generally considered as an inflammatory and immune disorder. 38 We observed increased VCAM-1 and ICAM-1 expression on the endothelium with cell infiltration in hearts and kidneys of hypertensive double-transgenic rats with high Ang II. Direct renin inhibition, Ang II receptor and endothelin receptor blockade, aspirin, or dexamethasone treatment all reduced NF-B activation and ameliorated inflammatory target organ damage in that rat model. 17, 30, 39, 40 Our earlier studies and the data presented here support the efficacy of antiinflammatory approaches to cardiovascular diseases. In our Tie-1-⌬N mice, NF-B inhibition in a single cell type, namely endothelial cells, promoted renal protection. As a consequence of suppressed endothelial NF-B activity, reduced VCAM-1 and ICAM-1 expression led to strongly decreased immune cell infiltration in the surrounding tissues. These infiltrating inflammatory cells synthesize and secrete various cytokines that could contribute locally to organ damage.
We focused our attention on the endothelium because this cell layer has been particularly implicated in target-organ damage through endothelial dysfunction mediated by nitric oxide synthase dysfunction, Ang II, and aldosterone. 41 We purposely selected a model that we were sure would cause sufficient target-organ damage in mice. 22 Our model with high Ang II and low nitric oxide availability mimics a pattern seen in patients with heart failure, diabetes mellitus, and arteriosclerosis, as reviewed elsewhere. 42 Nevertheless, our study should not be generalized to situations in which nitric oxide synthase is still active. A better understanding of the complexity of NF-B in the regulation of beneficial and detrimental effects is needed. Therefore, uniquely targeted models such as the one reported here can be extended to other cell types. The approach could give new insights into both pathogenesis and novel therapeutic options.
